checkAd
    Startseite > Aktien > Cartesian Therapeutics > Nachrichten
    Cartesian Therapeutics
    Aktie
    ISIN: US8162123025 WKN: A407YS SYM: RNAC Land USA
    Zur Watchlist hinzufügen Zum Portfolio hinzufügen
    31,10
     
    USD
    +1,20 %
    +0,37 USD
    Letzter Kurs 14:53:22 Nasdaq
    Geldkurs
    11.06.24
    30,61
     
    USD
    100 STK
    Briefkurs
    11.06.24
    30,77
     
    USD
    100 STK

    Cartesian Therapeutics Aktie kaufen

    Kauf
    Verkauf

    Neueste Nachrichten

    Cartesian Therapeutics Announces New Employment Inducement Grants
    06.05.24 · Business Wire (engl.) · Cartesian Therapeutics
    Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
    22.04.24 · Business Wire (engl.) · Cartesian Therapeutics
    Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
    04.04.24 · Business Wire (engl.) · Cartesian Therapeutics
    Cartesian Therapeutics Announces New Employment Inducement Grants
    04.04.24 · Business Wire (engl.) · Cartesian Therapeutics
    Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
    28.03.24 · globenewswire · Cartesian Therapeutics
    Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
    07.03.24 · globenewswire · Cartesian Therapeutics
    Cartesian Therapeutics to Participate in Upcoming Investor Conferences
    06.03.24 · globenewswire · Cartesian Therapeutics
    Cartesian Therapeutics Announces New Employment Inducement Grant
    05.03.24 · globenewswire · Cartesian Therapeutics
    Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
    05.03.24 · globenewswire · Cartesian Therapeutics
    Cartesian Therapeutics Announces New Employment Inducement Grants
    05.02.24 · globenewswire · Cartesian Therapeutics
    Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
    08.01.24 · globenewswire · Cartesian Therapeutics
    Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
    08.01.24 · globenewswire · Cartesian Therapeutics